IntegraGen is a genomics company focused on cancer and rare genetic diseases. Its mission is to bring molecular research into clinical practice by developing and commercializing molecular diagnostic tests based on genetic biomarkers. The company also supports genomic research through scientific expertise, sequencing technology, and data-analysis capabilities, serving academic and private laboratories, researchers, clinicians, biopharmaceutical companies, and contract research organizations.

Its services include next-generation sequencing and related laboratory work, such as genome, exome, and panel sequencing; RNA sequencing; methylation analysis; NGS library sequencing; genotyping; and sample extraction. IntegraGen also provides customized bioinformatics and biostatistics tools and analyses to help interpret genomic data. Its analysis solutions cover tumor genomics, gene expression, advanced genomic analysis, and constitutional genomics.

The company describes itself as an established provider of genomic platforms and services, with sequencing platforms used at recognized institutes. Through its combination of laboratory services and analytical solutions, IntegraGen aims to help researchers and clinical teams generate and interpret genomic insights for their work in oncology and genetic disease.